Jun 2 |
ALX Oncology Presents First Evorpacept Combination Data with an Antibody-Drug Conjugate from Phase 1 ASPEN-07 Clinical Trial in Patients with Advanced Bladder Cancer
|
May 31 |
Novartis (NVS) Reports Positive Long-Term Data on CSU Drug
|
May 31 |
Gilead's (GILD) Urothelial Cancer Study Did Not Meet Its Primary Goal
|
May 31 |
Ultragenyx (RARE) DTX401 Meets Goals in Metabolic Disorder Study
|
May 29 |
AstraZeneca (AZN) Falls on Failure to Meet NSCLC Study OS Goal
|
May 29 |
Prothena (PRTA), Bristol Myers Tie Up for Second Neuro Candidate
|
May 29 |
ALX Oncology Announces Participation in the Jefferies Global Healthcare Conference
|
May 28 |
Candel (CADL) Stock Skyrockets 431% Year to Date: Here's Why
|
May 27 |
Apellis (APLS) Posts Upbeat One-Year Kidney Diseases Study Data
|
May 24 |
Verastem (VSTM) Up on Upbeat Early Pancreatic Cancer Study Data
|